Laurus Labs | Business Upturn

Laurus Labs announces voluntary closure of Laurus Generics GmbH

Business Desk — Thu, 30 Apr 2026 10:07:02 +0000

Laurus Labs has announced the voluntary closure of its step-down wholly owned subsidiary, Laurus Generics GmbH, based in Germany. The decision was approved by the Board of Directors during their meeting on April 30, 2026.

Laurus Generics GmbH, which is not considered a material subsidiary of Laurus Labs, reported no turnover for the financial year ending March 31, 2026. The net worth of the subsidiary was recorded at a negative €10,53,091. The closure is not expected to have any material impact on Laurus Labs’ financials or operations, as stated by the company.

The closure process will proceed in accordance with the applicable laws in Germany and will be subject to necessary regulatory approvals. Laurus Labs has assured that it will inform the stock exchanges upon the completion of the closure process.

The Board meeting where this decision was made commenced at 2:00 p.m. and concluded at 3:00 p.m.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Laurus Labs approves €9.8 million investment in KRKA Pharma joint venture

Arunika Jain — Thu, 30 Apr 2026 10:05:22 +0000

Laurus Labs has announced a significant investment in its joint venture, KRKA Pharma Private Limited, amounting to up to €9.8 million. This strategic move, approved by the Board of Directors during their meeting on April 30, 2026, is aimed at supporting the joint venture’s capital expenditure plans for establishing a new manufacturing facility.

KRKA Pharma, a joint venture between Laurus Labs and KRKA d.d., Novo mesto, Slovenia, will also see an additional investment from KRKA d.d. amounting to approximately €10.2 million. The existing shareholding ratio will remain unchanged, with KRKA d.d. holding 51% and Laurus Labs maintaining a 49% stake.

The investment aligns with Laurus Labs’ long-term business objectives and strategic growth plans. The funds are expected to bolster KRKA Pharma’s capabilities in the pharmaceutical sector, where it currently operates. As of the financial year 2025-26, KRKA Pharma reported a turnover of ₹10.47 million.

The transaction qualifies as a related party transaction under SEBI regulations, given the common directors between Laurus Labs and KRKA Pharma. However, it is conducted at arm’s length, ensuring fairness and compliance with regulatory standards. The investment process is anticipated to conclude during the financial year 2026-27, with no governmental or regulatory approvals required.

KRKA Pharma, incorporated in April 2024, is yet to commence full-scale business operations but is currently engaged in research and development services. The joint venture is based in India and aims to expand its manufacturing capabilities through this investment.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Laurus Labs reports ₹6,813 crore revenue for FY26 with 23% growth

Arunika Jain — Thu, 30 Apr 2026 09:56:27 +0000

Laurus Labs has announced its financial results for the fiscal year ending March 31, 2026, reporting a revenue of ₹6,813 crore, marking a 23% increase over the previous year. The company achieved an EBITDA of ₹1,826 crore, reflecting a 64% growth, with EBITDA margins improving to 26.8% from 20.1% in FY25.

The Hyderabad-based pharmaceutical and biotech company attributed its robust performance to strong growth in its Contract Development and Manufacturing Organisation (CDMO) division and sustained demand across its complex chemistry platforms. The Affordable Medicines division also contributed significantly, with revenues reaching ₹4,733 crore, an 18% increase from the previous year.

In the fourth quarter of FY26, Laurus Labs reported revenues of ₹1,812 crore, a 5% year-on-year growth, and an EBITDA of ₹523 crore, up by 10% compared to Q4 FY25. The company’s gross margins for the quarter stood at 61.4%, an improvement from the previous year’s 54.5%.

Dr. Satyanarayana Chava, Founder and CEO of Laurus Labs, highlighted the company’s strategic investments in novel technologies and its resilient business model amidst macro-economic volatility. He noted the company’s continued progress in EHS/ESG initiatives and its focus on laying a foundation for future growth.

The CDMO division, particularly in small molecules, reported a 38% increase in revenues to ₹1,896 crore for FY26, driven by late-stage pipeline developments and commercial NCE API supplies. The Bio division also showed healthy growth, with revenues increasing by 15% to ₹184 crore.

Laurus Labs declared a second interim dividend of ₹1.2 per share during Q4 FY26. The company plans to increase its capital expenditure intensity over FY27-28 to support growth projects across various sectors, including small molecule, fermentation, peptides, and gene therapy/ADC.

The company completed 132 quality audits in FY26 without critical findings and was listed in the S&P Global Sustainability Yearbook for 2024 and 2025. Laurus Labs remains committed to the United Nations Global Compact’s sustainability principles.

An earnings conference call is scheduled for April 30, 2026, at 5:00 p.m. IST to discuss the results in detail.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Laurus Labs to invest ₹82 crore in joint venture and appoints two new independent directors

Kinjal — Thu, 30 Apr 2026 09:50:03 +0000

Laurus Labs Limited has announced significant strategic developments, including a substantial investment in its joint venture and the appointment of two new independent directors. The company’s board of directors approved these decisions during a meeting held on April 30, 2026.

The board has authorised an investment of up to ₹82 crore (equivalent to EURO 9.8 million) in KRKA Pharma Private Limited, a joint venture of Laurus Labs. This investment aligns with the company’s strategic growth plans and long-term business objectives, with funds earmarked for KRKA’s capital expenditure plans, including setting up a manufacturing facility. The existing shareholding ratio of 51:49 between KRKA d.d., Novo mesto and Laurus Labs will remain unchanged following this investment.

In addition to the investment, Laurus Labs has appointed Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as independent directors for a term of five years, effective from July 2, 2026. Dr. Mande is a distinguished structural and computational biologist with a rich background in research and academia, having served as Director General of the Council of Scientific and Industrial Research (CSIR) and Secretary of the Department of Scientific and Industrial Research (DSIR), Government of India. Ms. Banerjee brings over three decades of experience in the financial services industry and has been recognised as a thought leader in wealth management.

The board also noted the retirement of Mrs. Aruna Bhinge as an independent director, effective from the close of business hours on July 6, 2026. Mrs. Bhinge completed her second term as an independent director, serving from July 7, 2021, to July 6, 2026.

Furthermore, the board approved the voluntary closure of Laurus Generics GmbH, a step-down wholly owned subsidiary in Germany. The closure is in accordance with applicable German laws and will not materially impact Laurus Labs’ financials, as Laurus Generics GmbH is not a material subsidiary and reported nil turnover for the year ending March 31, 2026.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Laurus Labs receives creditor approval for composite scheme of arrangement

Yash Agarwal — Tue, 07 Apr 2026 11:46:37 +0000

Laurus Labs has announced that the meetings of unsecured creditors for its subsidiaries, Laurus Synthesis and Sriam Labs, have successfully concluded with approval for the Composite Scheme of Arrangement. The meetings were held on 6 April 2026, following directives from the National Company Law Tribunal (NCLT), Amravati Special Branch.

The Composite Scheme of Arrangement involves Laurus Synthesis Private Limited as the Demerged or Transferor Company and Sriam Labs Private Limited as the Resulting Company. Both entities are wholly-owned subsidiaries of Laurus Labs, which acts as the Transferee Company in the scheme. The arrangement is structured under Sections 230 to 232 of the Companies Act, 2013, along with the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016.

The meetings were convened in compliance with NCLT’s directions and applicable legal provisions. Laurus Labs confirmed that the requisite quorum was present, and the meetings were conducted in a fair and transparent manner. The approval by the unsecured creditors is considered a significant milestone in the implementation of the scheme.

However, the Composite Scheme of Arrangement still requires the approval of the Hon’ble NCLT and other statutory and regulatory authorities to proceed further.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Stocks hitting 52-week highs today, June 16: Bharat Electronics, Laurus Labs, Max Healthcare, JK Cement and more

Aman Shukla — Mon, 16 Jun 2025 10:25:28 +0000

Indian equity markets closed on a positive note on June 16, 2025, as benchmark indices posted strong gains across the board. The BSE Sensex surged 677.55 points (0.84%) to close at 81,796.15, while the NSE Nifty 50 climbed 227.90 points (0.92%) to settle at 24,946.50, just shy of the key 25,000 mark.

Amid this rally, several stocks hit fresh 52-week highs, signalling strong investor interest.

Stocks That Hit 52-Week Highs Today

Company	Market Price (₹)	Change (%)	52-Week High (₹)
Bharat Electronics	403.85	2.45%	404.50
Max Healthcare Institute	1,246.80	1.14%	1,250.00
Laurus Labs	680.25	2.05%	683.00
Muthoot Finance	2,633.30	1.33%	2,645.20
Max Financial Services	1,577.00	3.34%	1,586.80
Fiem Industries	1,944.50	2.76%	1,960.00
Force Motors	13,961.00	4.57%	14,100.00
Subros	987.90	18.81%	997.80
Strides Pharma Science	891.90	1.07%	901.05
Ramco Cements	1,070.85	0.78%	1,082.50
Narayana Hrudayalaya	1,934.10	1.10%	1,957.00
Maharashtra Scooters	15,135.00	4.27%	15,326.00
Nazara Technologies	1,332.10	0.32%	1,354.00
Shilpa Medicare	983.55	-0.23%	1,000.00
Karur Vysya Bank	248.55	0.31%	253.50
Manappuram Finance	278.81	-0.26%	284.90
JK Cement	5,978.50	-1.71%	6,145.00

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Stocks hitting 52-week highs today, April 23: Laurus Labs, UPL, Bharti Hexacom, HDFC Bank and more

Aman Shukla — Wed, 23 Apr 2025 10:31:27 +0000

The Indian equity markets ended Wednesday, April 23, 2025, on a bullish note with major benchmark indices witnessing a sharp rally.

The Nifty 50 surged past the 24,300 mark, closing at 24,328.95, up 161.70 points or 0.67%, while the BSE Sensex climbed 520.90 points to settle at 80,116.49, gaining 0.65%. As market sentiment remained upbeat, several stocks touched their 52-week highs during the day.

Here’s a look at some of the prominent stocks that scaled new 52-week highs on April 23, 2025:

UPL Ltd
The stock touched a fresh 52-week high of ₹682.00. It ended the session at ₹679.90, up 1.07%.
BSE Ltd
BSE shares continued their bullish trend, hitting a 52-week high of ₹6,459.00. The stock settled at ₹6,439.00, up 3.16%.
SBFC Finance
SBFC Finance surged to a 52-week high of ₹109.53. It closed at ₹108.26, marking a gain of 3.82%.
Krishna Institute of Medical Sciences (KIMS)
The healthcare stock hit a new 52-week high of ₹700.00. It closed at ₹691.30, up 1.13%.
Laurus Labs
The pharma company reached a 52-week high of ₹659.85. It closed at ₹650.70, down marginally by 0.15%.
HDFC Bank
India’s largest private bank hit a 52-week high of ₹1,978.90. The stock closed lower at ₹1,923.90, down 1.93%.
JK Cement
The stock touched a fresh 52-week high of ₹5,232.90 during the session. It ended at ₹5,081.60, down 1.36%.
Bharti Hexacom
The telecom player hit a 52-week high of ₹1,697.90. It closed at ₹1,646.70, up 0.32%.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Stocks hitting 52-week highs today, April 22: HDFC Bank, Laurus Labs, Bharti Hexacom, Eicher Motors and more

Aman Shukla — Tue, 22 Apr 2025 10:19:55 +0000

The Indian stock market continued its upward trajectory for the sixth consecutive trading session on April 22, 2025. Both benchmark indices ended in green, with the BSE Sensex rising by 187.09 points (0.24%) to 79,595.59, while the NSE Nifty 50 gained 41.70 points (0.17%), closing at 24,167.25.

Several stocks touched their 52-week highs during the session, indicating strong investor interest. Here are the notable stocks that touched their 52-week highs today:

HDFC Bank: Achieved a 52-week high of ₹1,970.60.
Aavas Financiers: Reached a 52-week high of ₹2,198.35.
Laurus Labs: Hit a 52-week high of ₹657.45.
JK Cement: Attained a 52-week high of ₹5,142.15.
UPL: Surged to a 52-week high of ₹674.25.
Bajaj Finance: Reached a 52-week high of ₹9,393.00.
Kotak Mahindra Bank: Achieved a 52-week high of ₹2,261.50.
Bharti Hexacom: Touched a 52-week high of ₹1,672.00.
Interglobe Aviation (IndiGo): Reached a 52-week high of ₹5,516.95.
Krishna Institute of Medical Sciences: Achieved a 52-week high of ₹688.20.
Eicher Motors: Reached a 52-week high of ₹5,906.50.
Chambal Fertilisers & Chemicals: Attained a 52-week high of ₹699.70.
SRF Ltd.: Hit a 52-week high of ₹3,085.00.
BSE Ltd.: Reached a 52-week high of ₹6,313.00.

Laurus Labs receives EIR from USFDA for API manufacturing facility (Unit-4) at Atchutapuram

Aman Shukla — Tue, 15 Apr 2025 06:37:53 +0000

Laurus Labs has announced the receipt of the Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its API manufacturing facility, Unit–4, located at Atchutapuram, Anakapalli District, Visakhapatnam, Andhra Pradesh.

The inspection was conducted by the USFDA from January 27 to January 31, 2025. The EIR confirms the completion of the inspection process and indicates the current compliance status of the facility with applicable US regulatory requirements.

This development follows Laurus Labs’ earlier intimation dated January 31, 2025, regarding the conclusion of the USFDA inspection at the site.

Unit–4 is one of Laurus Labs’ key active pharmaceutical ingredient (API) manufacturing sites, contributing to its global supply chain operations.

In the meantime, Laurus Labs shares opened at ₹611.55, reaching a high of ₹622.90 and a low of ₹608.80 during the session. The stock remains close to its 52-week high of ₹646.20, reflecting strong investor interest. With a 52-week low of ₹385.45, Laurus Labs has shown impressive recovery and momentum.

Laurus Labs stock jumps 5% after US grants emergency humanitarian waiver for HIV treatment

Aman Shukla — Thu, 30 Jan 2025 04:30:48 +0000

Laurus Labs’ stock price surged by 5% following the United States’ approval of an “emergency humanitarian waiver,” allowing continued access to HIV treatment across 55 countries.

This waiver, crucial for global health, ensures the continuation of life-saving assistance, including core medicines and medical services for HIV patients. UNAIDS welcomed the approval, emphasizing its role in sustaining vital health services worldwide.

In response to market concerns, Laurus Labs issued a clarification stating that any potential impact from a funding freeze would not significantly affect the company’s business. The company highlighted the robust market for Anti-Retroviral (ARV) drugs, which has a total market size of $1.5 billion, representing just 10% of the annual HIV financing budget.

Laurus Labs is a key player in the ARV market, with its extensive portfolio of treatments vital to global efforts against HIV. The approval of this humanitarian waiver is expected to strengthen the company’s position, given its critical role in providing essential medications to HIV-affected regions.

Laurus Labs’ stock opened at ₹565.95 and reached a high of ₹580.00, with a low of ₹557.40 for the day. The stock’s 52-week high stands at ₹619.40, while the 52-week low is ₹368.30.

Laurus Labs clarifies on reports of impact of Antiretroviral business, says no significant impact

Aman Shukla — Mon, 27 Jan 2025 08:37:02 +0000

Laurus Labs Limited has addressed recent media reports regarding the temporary freeze of funding under the US President’s Emergency Plan for AIDS Relief (PEPFAR) for 90 days. The company has clarified that this development is unlikely to significantly impact its business operations.

The global antiretroviral (ARV) medicine market stands at approximately $1.5 billion annually, representing only 10% of the total HIV financing budget. Funding for AIDS treatment comes from multiple sources, including country governments, PEPFAR, and the Global Fund. These global agencies have successfully collaborated to control the AIDS pandemic, ensuring medication procurement remains steady even during funding reviews.

Additionally, media reports highlight that the United States has recently decided to rejoin the World Health Organization (WHO), reinforcing its commitment to global health initiatives.

Laurus Labs believes this reinforces stability in global AIDS funding and assures stakeholders there is no immediate need for disclosure under Regulation 30 of the Listing Regulations.

The company remains confident that its operations and business will not face significant disruption due to this temporary funding review.

Laurus Labs shares fall 10% as ARV funding concerns weigh heavily

Aditya Bhagchandani — Mon, 27 Jan 2025 04:43:32 +0000

Shares of Laurus Labs fell sharply by 10% on January 27, 2025, closing at ₹542.40, amid negative sentiment triggered by reports of a potential halt in U.S. foreign aid funding for AIDS relief programs. The significant decline in the stock is attributed to its heavy reliance on antiretroviral (ARV) drug sales, which constitute nearly 50% of the company’s business.

Impact of Foreign Aid Pause

The foreign aid funding pause ordered by U.S. Secretary of State Marco Rubio, which includes the President’s Emergency Plan for AIDS Relief (PEPFAR), is expected to disrupt the provision of ARVs to millions globally. This pause raises concerns for Laurus Labs, as a major chunk of its revenue stems from supplying ARVs through PEPFAR and similar programs.

Broader Market Reaction

The news has also negatively impacted other Indian pharmaceutical companies involved in ARV production, such as Aurobindo Pharma, Cipla, and Strides. However, Laurus Labs faces the steepest impact due to its significant dependency on the ARV segment.

Stock Performance and Financials

Previous Close: ₹602.65
Day Range: ₹542.40 – ₹610.00
Market Cap: ₹292.49 billion
Year Range: ₹360.85 – ₹619.40

The broader sentiment around the stock remains bearish, with investors anticipating further volatility as the U.S. reviews its foreign aid programs.

While the pause in funding is under review and could potentially be reversed, the uncertainty surrounding the duration and implications of this decision poses a significant challenge for Laurus Labs. The company’s heavy reliance on ARV drug exports may require strategic shifts to mitigate the impact of geopolitical and policy risks.

Investors will also be closely watching the company’s upcoming quarterly results and management commentary for any updates on mitigating these challenges.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions.

Laurus Labs Q3 FY25 Financial Results: Revenue up 18.4% YoY to Rs 1415.05 crore, Net Profit up 297% YoY

Aditya Bhagchandani — Fri, 24 Jan 2025 09:33:35 +0000

Laurus Labs Limited has released its consolidated unaudited financial results for the quarter ended December 31, 2024. The results highlight steady performance across revenue and profitability metrics.

Key Financial Highlights (Q3 FY25 vs Q3 FY24):

Revenue from Operations: ₹1,415.05 crore, up 18.4% from ₹1,194.92 crore in Q3 FY24.
Total Income: ₹1,424.47 crore, an increase of 18.9% YoY from ₹1,197.35 crore.
Net Profit: ₹92.89 crore, a growth of 297% YoY compared to ₹23.34 crore in the same quarter last year.
EBITDA: ₹218.26 crore, reflecting robust operational efficiency.

Nine-Month Performance:

Revenue from Operations: ₹3,833.66 crore, up 6.5% YoY from ₹3,601.16 crore.
Net Profit: ₹125.57 crore, a significant increase from ₹62.27 crore, reflecting improved profitability.

Operational Highlights:

The company achieved higher revenue from its active pharmaceutical ingredient (API) and formulation businesses.
Cost of materials consumed was ₹653 crore in Q3 FY25, slightly down from ₹634.12 crore in Q3 FY24, indicating better cost efficiency.
Total expenses rose to ₹1,293.79 crore in Q3 FY25 compared to ₹1,162.73 crore in Q3 FY24, mainly due to higher employee benefit and depreciation expenses.

Laurus Labs inaugurates new R&D facility at IKP Knowledge Park, Telangana

Aman Shukla — Mon, 16 Sep 2024 08:54:49 +0000

Laurus Labs Ltd has recently announced the opening of its modern new R&D centre at IKP Knowledge Park, Plot No. DS15, Kolthur Shamirpet Medchal Telangana.

The facility was officially inaugurated by Honourable Shri Duddilla Sridhar Babu Garu, Minister of Information Technology, Electronics and Communications, Industries and Commerce and Legislative Affairs – Government of Telangana, as well as Dr. Satyanarayana Chava, Founder and CEO of Laurus Labs, and other senior management team members. The modern facility is designed to promote innovation while advancing the company’s goal of developing “Chemistry for Better Living.”

Laurus Labs is investing ₹250 crore to establish the new R&D center, featuring a 2,00,000-square-foot facility with state-of-the-art laboratories and infrastructure. This new center is designed to support its CDMO business and will create job opportunities for over 800 individuals.

Laurus Labs passes US FDA inspection for API manufacturing facility in Hyderabad

Aman Shukla — Fri, 13 Sep 2024 12:34:10 +0000

Laurus Labs Ltd has recently informed exchanges that the company successfully completed the US Food and Drug Administration (US FDA) audit of its API manufacturing plant in Hyderabad.

The audit resulted in zero Form 483 observations, highlighting Laurus Labs’ dedication to maintaining the highest standards of compliance, safety and quality.

In the exchange filing, the company also shared, “The US FDA inspection, conducted from 9th to 13th September, focused on evaluating the facility’s adherence to global regulatory requirements and best practices. Laurus Labs’ API manufacturing facility, located at DS-1, IKP Knowledge Park, Genome Valley, Shameerpet, Telangana is instrumental in developing Active Pharmaceutical Ingredients, bolstering the company’s ability to deliver high-quality, innovative pharmaceutical solutions to its global customers.”

Laurus Labs share jumps 5% after US House passes Biosecure Act

Aman Shukla — Tue, 10 Sep 2024 05:09:18 +0000

Laurus Labs’ stock rose more than 5% in early trading after the US House of Representatives passed the Biosecure Act, which aims to strengthen the pharmaceutical supply chain and promote domestic domestic drug production. The news was well received by investors and major pharmaceutical firms saw rises in the market.

The stock stock opened at ₹495.90. The stock hit a day high of ₹518.00 and a low of ₹494.75. The company’s market capitalization reached ₹27,642.70 crore. Laurus Labs’s 52-week high is ₹518.00, while the 52-week low is ₹349.40.

The Biosecure Act is expected to provide Indian pharmaceutical companies with more benefits in the US market, which would boost the sector’s objectives.

As of 10:37 am, Laurus Labs shares were trading 3.82% higher at Rs 509.70 on the NSE.

Laurus Labs faces 9% stock plunge as December quarter results disappoint investors

Aditya Bhagchandani — Thu, 25 Jan 2024 04:28:21 +0000

Laurus Labs Ltd. witnessed a significant downturn, with its shares plummeting as much as 9% in early trade on Thursday, marking the largest single-day drop since May 2020. This sharp decline followed the company’s disappointing December quarter results that fell short of street expectations.

The December quarter reported an EBITDA margin of 15.3%, prompting the management to express confidence that operating leverage would propel margins back above 20% in the next financial year.

The company’s December quarter results revealed a net profit decline to ₹20 crore from ₹200 crore last year, while revenue also contracted by 22%, attributed to a high base. Adjusting for a large purchase order in the base quarter, the management highlighted an 11% growth in revenue for the December quarter.

Laurus Labs faced an increase in net leverage, with net debt to EBITDA on a trailing 12-month basis rising to 3x for the quarter ending December, compared to 1.9x in September and 1.3x in the same quarter last year.

As of 9:55 am, Laurus Labs shares continued their descent, trading 6.12% lower at ₹376.35.

US FDA issues 5 observations to Laurus Labs’ subsidiary at Vishakapatnam

Dimple Gehlot — Tue, 12 Dec 2023 13:11:49 +0000

Laurus Synthesis Private Limited (LSPL), a fully-owned subsidiary of Laurus Labs, has recently undergone an inspection by the US Food and Drug Administration (FDA) for its manufacturing facility located in Parawada, Anakapalli, near Visakhapatnam, Andhra Pradesh. The inspection spanned from December 4, 2023, to December 12, 2023.

Following the inspection, LSPL has received a Form 483 with five observations from the FDA. The company is committed to promptly addressing these observations within the stipulated timelines. The Form 483 is a standard form issued by the FDA to notify companies of any deviations or concerns observed during inspections. Laurus Labs aims to ensure compliance with regulatory standards and maintain the highest quality standards in its manufacturing processes.

Laurus Labs, a multinational pharmaceutical and biotechnology company based in Hyderabad, India, specialises in active pharmaceutical ingredients, generic formulations, custom synthesis, biotechnology, veterinary APIs, and agrochemicals.

Laurus Labs to acquire additional 7.24% stake in ImmunoACT for Rs.80 crores

News Desk — Wed, 31 May 2023 14:32:33 +0000

Laurus Labs made the announcement on Thursday that it has signed definitive agreements to acquire an additional stake of 7.24% in Immunoadoptive Cell Therapy Private Limited (ImmunoACT), an advanced cell and gene therapy company in exchange for a cash consideration of Rs.80 Crore. The company made the announcement through an exchange filing.

After the transaction is completed, Laurus Lab’s fully diluted share in ImmunoACT will climb to 33.86%, bringing the company’s total ownership to 33.86%. This new injection of capital will make it possible for ImmunuACT to expedite the additional supply of the lead candidate, HCAR-19, as well as the fighter expansion of the multi-location GMP facilities for manufacturing Chimeric Antigen Receptor T Cells (CAR-T cells) treatment to support the growing demand for scalable manufacturing. In addition, some founders and senior management of Laurus Labs would make secondary acquisitions in ImmunoACT to acquire a 0.54% ownership in the company (prior to this investment) for roughly 4 crore rupees at the same price and conditions.

ImmunoACT is now performing Phase II research at a number of hospitals, including Tata Memorial Hospital, thanks to a prior investment made by Laurus Labs in the company in November 2021. This investment enabled ImmunoACT to successfully create a GMP manufacturing facility at Navi Mumbai, in addition to a state-of-the-art R&D facility at the same location. Phase I findings that revealed a favorable balance of effectiveness and toxicity with low-grade cytokine release syndrome were presented at the American Society of Haematology (ASH) in November of 2022.

Laurus Labs’ dedication to gaining access to cutting-edge Cell and Gene Therapy technology has been further bolstered by this investment, which also makes the treatment more affordable for patients. With the support of this financing, ImmunoACT will be able to better prepare for the production of further medicines. This purchase is also a step towards our commitment to promoting and accessing breakthrough technology and making it economically viable in the unmet medical needs of autoimmune disorders and cancer. Specifically, this goal is being fulfilled in part via this acquisition. According to Dr. Satyanarayyana Chava, the Founder and Chief Executive Officer of the company, “We are looking to invest further in disruptive innovation with a disciplined approach, in order to enable our strategic partners and customers to bring these promising therapies to patients.”

Laurus Labs buys 72.55 percent stake in Richcore Life Sciences

Shlok Arya — Wed, 25 Nov 2020 18:16:49 +0000

Laurus Labs signed an agreement to acquire a 772.55 percent stake of Richcore’s shares from Eight Roads Venture and Ventureast for a value of Rs 246.7 crores.

Richcore has advanced R&D and manufacturing facilities, develops and manufacturing biotech products critical for manufacturing biological drugs. It aims to develop and grow its bioprocesses by providing contract research, development, and manufacturing services.

The current promoters of Richcore, Subramani Ramachandrappa will continue this position and will also be responsible for its management and operations. Laurus Lab will control its internal accruals and this acquisition will be revenue and PAT accretive.

CEO of Laurus Labs, Dr Satyanarayana Chava said, “Laurus will bring scale to Richcore’s operations and can become a major player in the biotech CDMO space. This will also help Laurus in becoming a leader in biocatalysts as Richcore brings significant expertise in enzyme development for pharmaceutical and other industrial applications.”

Richcore Lifesciences, CMD, Subramani Ramchandrappa said, “Richcore and Laurus Labs’ coming together marks the convergence of biotechnology and chemistry faculties. Leveraging the synergies arising from Laurus’s experience and Richcore’s innovation, we plan to build as we continue to serve our existing customers and enter new biotech segments.”